Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00461084 · ClinicalTrials.gov registry record
Biaxin Based Antibiotic Therapy in Previously Untreated, Advanced Stage Indolent Lymphoma
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 36
- Enrollment target
NCT00461084: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00461084 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00461084 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to see if a treatment with Biaxin (clarithromycin) which is an antibiotic given by mouth for 3 months can delay the growth of your lymphoma or shrink the lymphoma. We would also like to see how Biaxin (clarithromycin) works on lymphoma and blood cells.There is some evidence that this medication may change the behavior of lymphocytes, in addition to its known anti-infection activity.
Interventions
- DRUG BIAXIN (CLARITHROMYCIN)
- DRUG Biaxin (clarithromycin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2007-04 |
| Est. Completion | 2014-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00461084
The ClinicalTrials.gov registry entry for NCT00461084 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BIAXIN (CLARITHROMYCIN) is the first listed.
NCT00461084 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00461084 about?
NCT00461084 is a clinical study titled "Biaxin Based Antibiotic Therapy in Previously Untreated, Advanced Stage Indolent Lymphoma". The purpose of this study is to see if a treatment with Biaxin (clarithromycin) which is an antibiotic given by mouth for 3 months can delay the growth of your lymphoma or shrink the lymphoma. We would also like to see how Biaxin (clarithromycin) works on lymphoma and blood cells.There is some evide...
What is the current status of trial NCT00461084?
This trial is currently completed. The enrollment target is 36 participants. The study started on 2007-04. Estimated completion is 2014-09.
What interventions are being tested in trial NCT00461084?
The interventions under investigation include: BIAXIN (CLARITHROMYCIN) (DRUG), Biaxin (clarithromycin) (DRUG).
Who is sponsoring clinical trial NCT00461084?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.